Search Results - cheng-yong+shen

1 Results

Sort By:

The Current State of the Art: HER2 (also known as ErbB2), a receptor tyrosine kinase is overexpressed in around 25% of breast cancer cells. It is a known anti-cancer target to the monoclonal antibody, Trastuzumab. Limitation of the Current Art: However, about 20% patients develop resistance to Trastuzumab. Pertuzumab, Lapatinib, and other trastuzumab...

Published: 3/31/2022 | Inventor(s): Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yanmei Tao, Shiwen Luo

Keywords(s):

Category(s): Therapeutics